Fig. 4From: The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trialThe P-selectin Ag expression on platelet surface changes after 26 weeks of treatment from baseline. A significant reduction observed in mean MFI between 2 study arms (P < 0.05)Back to article page